PMID- 21030936
OWN - NLM
STAT- MEDLINE
DCOM- 20110210
LR  - 20101029
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 101
IP  - 4
DP  - 2010 Aug
TI  - Diabetic specific aspects in antithrombotic therapy in patients with coronary 
      artery disease.
PG  - 239-53
AB  - The use of combined antithrombotic medication in optimal dosages is mandatory for 
      diabetic patients. Moreover, specific antiplatelet therapy in DM has been shown 
      to reduce early and late atherothrombotic events in patients referred for 
      elective and acute angiography and intervention as well as for secondary 
      prevention of recurrent ischemic events in patients with coronary artery disease 
      (CAD). Among these antiplatelet agents prasugrel has been recently demonstrated 
      to lower adverse events in diabetic patients with acute coronary syndromes (ACS) 
      significantly more effective than clopidogrel without increasing severe bleeding 
      hazards. Also glycoprotein IIb-IIIa receptor inhibitors (GPI) had a greater 
      effect in diabetic subjects with ACS undergoing percutaneous coronary 
      intervention (PCI) on adverse clinical events compared to non-diabetics. In 
      contrast to antiplatelet therapy, all commercially available antithrombins except 
      enoxaparin have been shown to be equal or less effective in diabetics compared to 
      non-diabetics. Enoxaparin was superior to unfractionated heparin (UFH) in 
      reducing adverse events in diabetics with acute ST-elevation myocardial 
      infarction (STEMI) undergoing thrombolytic therapy. The role of several new 
      antithrombins, i.e. direct factor Xa inhibitors or direct antithrombins in 
      diabetic patients with stable or unstable CAD is still under investigation.
FAU - Farhan, S
AU  - Farhan S
AD  - Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, 
      Vienna, Austria. serdar.farhan@wienkav.at
FAU - Hochtl, T
AU  - Hochtl T
FAU - Wojta, J
AU  - Wojta J
FAU - Huber, K
AU  - Huber K
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Blood Coagulation/physiology
MH  - Blood Platelets/physiology
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - Diabetes Mellitus/*blood
MH  - Diabetic Angiopathies/blood/drug therapy
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2010/10/30 06:00
MHDA- 2011/02/11 06:00
CRDT- 2010/10/30 06:00
PHST- 2010/10/30 06:00 [entrez]
PHST- 2010/10/30 06:00 [pubmed]
PHST- 2011/02/11 06:00 [medline]
AID - R10103093 [pii]
PST - ppublish
SO  - Minerva Med. 2010 Aug;101(4):239-53.